SpringWorks Therapeutics (NASDAQ:SWTX) Given $32.50 Consensus Target Price by Analysts

Shares of SpringWorks Therapeutics (NASDAQ:SWTX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Analysts have set a 12-month consensus price target of $32.50 for the company and are anticipating that the company will post ($0.45) EPS for the current quarter, according to Zacks. Zacks has also given SpringWorks Therapeutics an industry rank of 83 out of 255 based on the ratings given to related companies.

SWTX has been the topic of a number of recent research reports. JPMorgan Chase & Co. initiated coverage on shares of SpringWorks Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $32.00 price objective on the stock. Goldman Sachs Group initiated coverage on shares of SpringWorks Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating and a $37.00 price objective on the stock. Wedbush initiated coverage on shares of SpringWorks Therapeutics in a research note on Tuesday, October 8th. They issued an “outperform” rating and a $33.00 price objective on the stock. Finally, Cowen initiated coverage on shares of SpringWorks Therapeutics in a research note on Tuesday, October 8th. They issued an “outperform” rating on the stock.

In other news, major shareholder Bain Capital Life Sciences Inv purchased 150,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $2,700,000.00. Also, Director Stephen P. Squinto purchased 275,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $4,950,000.00.

NASDAQ SWTX traded up $0.25 during trading on Wednesday, reaching $19.28. The company’s stock had a trading volume of 54,389 shares, compared to its average volume of 219,452. SpringWorks Therapeutics has a twelve month low of $17.66 and a twelve month high of $28.62.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

Further Reading: Understanding Market Liquidity

Get a free copy of the Zacks research report on SpringWorks Therapeutics (SWTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.